PDS Biotech’s Trial Shows Promising Cancer Survival Rates

NetScientific (GB:EMVC) has released an update.

PDS Biotechnology, a portfolio company of EMV Capital plc, reported impressive results from its IMMUNOCERV Phase 2 clinical trial at the ASTRO Annual Meeting 2024. The trial, which tested Versamune® HPV with chemoradiation in patients with locally advanced cervical cancer, achieved an 84.4% overall survival rate at 36 months, significantly higher than the historical average of 64%. The company is poised for further development of this promising immunotherapy, which has shown to be safe with minimal toxicity.

For further insights into GB:EMVC stock, check out TipRanks’ Stock Analysis page.